Summary Notice of Pendency of Class Action

NEW YORK--(BUSINESS WIRE)--To all persons and entities that purchased or otherwise acquired publicly traded Instadose Pharma Corp. (“Instadose”) securities from July 14, 2021, through November 24, 2021, both dates inclusive (collectively, the “Class”, and individually “Class Members”).

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an order of the United States District Court for the Eastern District of Virginia (the “Court”), that you may be a member of a class action pending in the Court. The lawsuit captioned DeLuca v. Instadose Pharma Corp., et al., Case No. 2:21-cv-00675, has been certified by the Court as a class action on behalf of the Class defined above. Please note that at this time, there is no judgment, settlement, or monetary recovery, and there is no guarantee there will be any recovery.

This case began in December 2021 and alleges claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The Action alleges that Defendants made material misrepresentations and omissions during the Class Period about due diligence performed into the business combination of Instadose with a Canadian-based cannabis producer. The Action is ongoing, but Defendants have failed to answer the complaint or make an appearance and therefore a renewed motion for default judgment will be filed pursuant to the Court’s order.

IF YOU ARE A CLASS MEMBER, YOUR RIGHTS WILL BE AFFECTED BY THIS ACTION. A Postcard Notice is currently being mailed to known potential Class Members. If you have not received a Postcard Notice, you may obtain a copy of it or the long-form Notice by downloading them from Class Counsel’s website at www.bespc.com/cases/InstadosePharma-SecuritiesLitigation or contacting the Administrator at:

Instadose Securities Litigation
c/o RG/2 Claims Administration LLC
P.O. Box 59479
Philadelphia, PA 19102-9479
[e-mail]
1-866-742-4955

Inquiries, other than requests for the notices, may be made to Class Counsel at:

Lawrence P. Eagel
BRAGAR EAGEL & SQUIRE, P.C.
810 Seventh Avenue, Suite 620
New York, NY 10019
Telephone: [phone]
www.bespc.com

At this time, Class Members are not required to take any action to remain in the Class other than retain documentation reflecting transactions and holdings in Instadose securities. If any benefits are eventually obtained for the Class as a result of this lawsuit, eligible Class Members may be entitled to a payment.

Class Members may choose to exclude themselves from the Class. If you exclude yourself, you will not be entitled to a payment if any benefits are eventually obtained for the Class. If you do not exclude yourself, you will be bound by any judgment in this litigation, whether favorable or unfavorable. To request exclusion, you must submit a written request for exclusion postmarked no later than February 14, 2024, in accordance with instructions set forth in the long-form Notice available at www.bespc.com/cases/InstadosePharma-SecuritiesLitigation.

Class Members are represented by Class Counsel. Class Members may also enter an appearance through an attorney if the member so desires. If you do, your attorney must file a notice of appearance with the Court on or before February 14, 2024.

This notice is only a summary. For more information please visit: www.bespc.com/cases/InstadosePharma-SecuritiesLitigation .

PLEASE DO NOT CONTACT THE COURT REGARDING THIS NOTICE